Effect of filgotinib on QT interval prolongation in healthy subjects

Trial Profile

Effect of filgotinib on QT interval prolongation in healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Dec 2017

At a glance

  • Drugs Filgotinib (Primary)
  • Indications Ankylosing spondylitis; Crohn's disease; Cutaneous lupus erythematosus; Inflammation; Lupus nephritis; Psoriatic arthritis; Rheumatoid arthritis; Sjogren's syndrome; Ulcerative colitis; Uveitis
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Dec 2017 New trial record
    • 08 Nov 2017 Results presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top